Differential splicing generates new transmembrane receptor and extracellular matrix-related targets for antibody-based therapy of cancer

Cancer Genomics and Proteomics

Volumn 8, Issue 5, 2011, Pages 211-226

  Weidle, Ulrich H ^a   Maisel, Daniela ^a   Klostermann, Stefan ^a   Weiss, Elisabeth H ^b   Schmitt, Manfred ^c  

^a ROCHE DIAGNOSTICS GMBH   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Angiogenesis; Constitutive signalling; Exon deletion and insertion; Hallmarks of cancer; Immunocytokines; Neo epitope(s); Review; Therapeutic window; Tumor targeting; Tumor specific targets

Indexed keywords

ANTIBODY; CELL ADHESION MOLECULE; CLAUDIN 18; EPITHELIAL CELL ADHESION MOLECULE; FIBRONECTIN; HERMES ANTIGEN; MEMBRANE PROTEIN; NERVE CELL ADHESION MOLECULE L1; OSTEOPONTIN; SCLEROPROTEIN; TENASCIN; TYROSINE KINASE RECEPTOR; VERSICAN;

ALTERNATIVE RNA SPLICING; ANGIOGENESIS; CANCER THERAPY; EXTRACELLULAR MATRIX; GENOMICS; REVIEW;

EID: 80054678708     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Review

References (124)

1. Chen Y, Peng C, Li D and Li S: Molecular and cellular bases of chronic myeloid leukemia. Protein Cell 1: 124-132, 2010.
2. Dienstmann R, Martinez P and Felip E: Personalizing therapy with targeted agents in non-small cell lung cancer. Oncotarget 2: 165-177, 2011.
3. Pierotti MA, Tamborini E, Negri T, Pricl S and Pilotti S: Targeted therapy in GIST: in silico modeling for prediction of resistance. Nat Rev Clin Oncol 8: 161-170, 2011.
4. Gajewski TF: Molecular profiling of melanoma and the evolution of patient-specific therapy. Semin Oncol 38: 236-242, 2011.
5. Crystal AS and Shaw AT: New targets in advanced NSCLC: EML4-ALK. Clin Adv Hematol Oncol 9: 207-214, 2011.
6. Srebrow A and Kornblihtt AR: The connection between splicing and cancer. J Cell Sci 119: 2635-2641, 2006. (Pubitemid 44184000)
7. Skotheim RI and Nees M: Alternative splicing in cancer: noise, functional, or systematic? Int J Biochem Cell Biol 39: 1432-1449, 2007.
8. Brinkman BM: Splice variants as cancer biomarkers. Clin Biochem 37: 584-594, 2004.
9. Sharp PA: Split genes and RNA splicing. Cell 77: 805-815, 1994.
10. Hudson DL, Sleeman J and Watt FM: CD44 is the major peanut lectin-binding glycoprotein of human epidermal keratinocytes and plays a role in intercellular adhesion. J Cell Sci 108: 1959-1970, 1995.
11. Arch R, Wirth K, Hofmann M, Ponta H, Matzku S, Herrlich P and Zöller M: Participation in normal immune responses of a metastasis-inducing splice variant of CD44. Science 257: 682-685, 1992.
12. Weg-Remers S, Ponta H, Herrlich P and König H: Regulation of alternative pre-mRNA splicing by the ERK MAP-kinase pathway. EMBO J 20: 4194-4203, 2001. (Pubitemid 32751835)
13. Matter N, Herrlich P and König H: Signal-dependent regulation of splicing via phosphorylation of Sam68. Nature 420: 691-695, 2002. (Pubitemid 36764503)
14. Munoz MJ, de la Mata M and Kornblihtt AR: The carboxy terminal domain of RNA polymerase II and alternative splicing. Tends Biochem Sci 35: 497-504, 2010.
15. Luco RF, Pan Q, Tominaga K, Blencowe BJ, Pereira-Smith OM and Misteli T: Regulation of alternative splicing by histone modifications. Science 327: 996-1000, 2010.
16. David CJ, Chen M, Assanah M, Canoll P and Manley JL: HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 463: 364-368, 2009.
17. Warburg O: On respiratory impairment in cancer cells. Science 124: 269-270, 1956.
18. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL and Cantley LC: The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452: 230-233, 2008. (Pubitemid 351380249)
19. Van der Heiden MG, Cantley LC and Thompson CB: Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324: 1029-1033, 2009.
20. Beenken A and Mohammadi M: The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 8: 235-253, 2009.
21. Turner N and Grose R: Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 10: 116-129, 2010.
22. Knights V and Cook SJ: De-regulated FGF receptors as therapeutic targets in cancer. Pharmacol Ther 125: 105-117, 2010.
23. Toyokawa T, Yashiro M and Hirakawa K: Co-expression of keratinocyte growth factor and K-sam is an independent prognostic factor in gastric carcinoma. Oncol Rep 21: 875-880, 2009.
24. Turner N, Lambros MB, Horlings HM, Pearson A, Sharpe R, Natrajan R, Geyer FC, van Kouwenhove M, Kreike B, Mackay A, Ashworth A, van de Vijver MJ and Reis-Filho JS: Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 29: 2013-2023, 2010.
25. Bai A, Meetze K, Vo NY, Kollipara S, Mazsa EK, Winston WM, Weiler S, Poling LL, Chen T, Ismail NS, Jiang J, Lerner L, Gyuris J and Weng Z: GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling. Cancer Res 70: 7630-7639, 2010.
26. Knowles MA: Novel therapeutic targets in bladder cancer: mutation and expression of FGF receptors. Future Oncol 4: 71-83, 2008. (Pubitemid 351372608)
27. Rexer BN, Engelman JA and Arteaga CL: Overcoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonists. Cell Cycle 8: 18-22, 2009.
28. Batra SK, Castelino-Prabhu S, Wikstrand CJ, Zhu X, Humphrey PA, Friedman HS and Bigner DD: Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ 6: 1251-1259, 1995.
29. Grandal MV, Zandi R, Pedersen MW, Willumsen BM, van Deurs B and Poulsen HS: EGFRvIII escapes down-regulation due to impaired internalization and sorting to lysosomes. Carcinogenesis 28: 1408-1417, 2007. (Pubitemid 47241789)
30. Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M, Sawaya R and Aldape K: Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 11: 1462-1466, 2005. (Pubitemid 40315227)
31. Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, Hunt JL, Freilino ML, Graner MW, Wikstrand CJ, Bigner DD, Gooding WE, Furnari FB and Grandis JR: Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 12: 5064-5073, 2006. (Pubitemid 44453332)
32. Moscatello DK, Holgado-Madruga M, Godwin AK, Ramirez G, Gunn G, Zoltick PW, Biegel JA, Hayes RL and Wong AJ: Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 55: 5536-5539, 1995.
33. Sampson JH, Crotty LE, Lee S, Archer GE, Ashley DM, Wikstrand CJ, Hale LP, Small C, Dranoff G, Friedman AH, Friedman HS and Bigner DD: Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc Natl Acad Sci USA 97: 7503-7508, 2000. (Pubitemid 30431493)
34. Yang W, Barth RF, Wu G, Kawabata S, Sferra TJ, Bandyopadhyaya AK, Tjarks W, Ferketich AK, Moeschberger ML, Binns PJ, Riley KJ, Coderre JA, Ciesielski MJ, Fenstermaker RA and Wikstrand CJ: Molecular targeting and treatment of EGFRvIII-positive gliomas using boronated monoclonal antibody L8A4. Clin Cancer Res 12: 3792-3802, 2006. (Pubitemid 44000261)
35. Johns TG, Stockert E, Ritter G, Jungbluth AA, Huang HJ, Cavenee WK, Smyth FE, Hall CM, Watson N, Nice EC, Gullick WJ, Old LJ, Burgess AW and Scott AM: Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene. Int J Cancer 98: 398-408, 2002. (Pubitemid 34188683)
36. Johns TG, Luwor RB, Murone C, Walker F, Weinstock J, Vitali AA, Perera RM, Jungbluth AA, Stockert E, Old LJ, Nice EC, Burgess AW and Scott AM: Antitumor efficacy of cytotoxic drugs and me monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478. Proc Natl Acad Sci USA 100: 15871-15876, 2003. (Pubitemid 38021082)
37. Mishima K, Johns TG, Luwor RB, Scott AM, Stockert E, Jungbluth AA, Ji XD, Suvarna P, Voland JR, Old LJ, Huang HJ and Cavenee WK: Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Res 67: 5349-5354, 2001. (Pubitemid 32694908)
38. Luwor RB, Johns TG, Murone C, Huang HJ, Cavenee WK, Ritter G, Old LJ, Burgess AW and Scott AM: Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. Cancer Res 61: 5355-5361, 2001. (Pubitemid 32694909)
39. Scott AM, Lee FT, Tebbutt N, Herbertson R, Gill SS, Liu Z, Skrinos E, Murone C, Saunder TH, Chappell B, Papenfuss AT, Poon AM, Hopkins W, Smyth FE, MacGregor D, Cher LM, Jungbluth AA, Ritter G, Brechbiel MW, Murphy R, Burgess AW, Hoffman EW, Johns TG and Old LJ: A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci USA 104: 4071-4076, 2007. (Pubitemid 47181580)
40. Wang H, Zhou M, Shi B, Zhang Q, Jiang H, Sun Y, Liu J, Zhou K, Yao M, Gu Y, Yang S, Mao Y and Li Z: Identification of an exon 4-deletion variant of epidermal growth factor receptor with increased metastasis-promoting capacity. Neoplasia 13: 461-472, 2011.
41. Ronsin C, Muscatelli F, Mattei MG and Breathnach R: A novel putative receptor protein tyrosine kinase of the met family. Oncogene 8: 1195-1202, 1993.
42. Gaudino G, Follenzi A, Naldini L, Collesi C, Santoro M, Gallo KA, Godowski PJ and Comoglio PM: RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP. EMBO J 13: 3524-3532, 1994. (Pubitemid 24246189)
43. Wang MH, Ronsin C, Gesnel MC, Coupey L, Skeel A, Leonard EJ and Breathnach R: Identification of the RON gene product as the receptor for the human macrophage stimulating protein. Science 266: 117-119, 1994. (Pubitemid 24345331)
44. Wagh PK, Peace BE and Waltz SE: Met-related receptor tyrosine kinase RON in tumor growth and metastasis. Adv Cancer Res 100: 1-33, 2008. (Pubitemid 351942429)
45. Benvenuti S, Lazzari L, Arnesano A, Li Chiavi G, Gentile A and Comoglio PM: RON kinase transphosphorylation sustains MET oncogene addiction. Cancer Res 71: 1945-1955, 2011.
46. O'Toole JM, Rabenau KE, Burns K, Lu D, Mangalampalli V, Balderes P, Covino N, Bassi R, Prewett M, Gottfredsen KJ, Thobe MN, Cheng Y, Li Y, Hicklin DJ, Zhu Z, Waltz SE, Hayman MJ, Ludwig DL and Pereira DS: Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member. Cancer Res 66: 9162-9170, 2006. (Pubitemid 44521136)
47. Zhou YQ, He C, Chen YQ, Wang D and Wang MH: Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potential. Oncogene 22: 186-197, 2003. (Pubitemid 36174176)
48. Wang MH, Kurtz AL and Chen Y: Identification of a novel splicing product of the RON receptor tyrosine kinase in human colorectal carcinoma cells. Carcinogenesis 21: 1507-1512, 2000. (Pubitemid 30603978)
49. Chen YQ, Zhou YQ, Angeloni D, Kurtz AL, Qiang XZ and Wang MH: Overexpression and activation of the RON receptor tyrosine kinase in a panel of human colorectal carcinoma cell lines. Exp Cell Res 261: 229-238, 2000.
50. van der Gun BT, Melchers LJ, Ruiters MH, de Leij LF, McLaughlin PM and Rots MG: EpCAM in carcinogenesis: the good, the bad or the ugly. Carcinogenesis 31: 1913-1921, 2010.
51. Liu SH, Michelson K, Rodriguez M, Macina R A and Papkoff J: A novel splice variant of human Ep-CAM as a potential therapeutic antibody target for epithelial cell-based cancers. Proc Amer Assoc Cancer Res 46, Abstract #2706, 2005
52. Weidle UH, Eggle D and Klostermann S: L1-CAM as a target for treatment of cancer with monoclonal antibodies. Anticancer Res 29: 4919-4931, 2009.
53. Coutelle O, Nyakatura G, Taudien S, Elgar G, Brenner S, Platzer M, Drescher B, Jouet M, Kenwrick S and Rosenthal A: The neural cell adhesion molecule L1: genomic organisation and differential splicing is conserved between man and the pufferfish Fugu. Gene 208: 7-15, 1998. (Pubitemid 28085270)
54. Euer NI, Kaul S, Deissler H, Möbus VJ, Zeillinger R and Weidle UH: Identification of LlCAM, Jagged2 and Neuromedin U as ovarian cancer-associated antigens. Oncol Rep 13: 375-387, 2005.
55. Gouveia RM, Gomes CM, Sousa M, Alves PM and Costa J: Kinetic analysis of L1 homophilic interaction: role of the first four immunoglobulin domains and implications on binding mechanism. J Biol Chem 283: 28038-28047, 2008.
56. Kamiguchi H, Long KE, Pendergast M, Schaefer AW, Rapoport I, Kirchhausen T and Lemmon V: The neural cell adhesion molecule L1 interacts with the AP-2 adaptor and is endocytosed via the clathrin-mediated pathway. J Neurosci 18: 5311-5321, 1998. (Pubitemid 28311948)
57. Jouet M, Rosenthal A and Kenwrick S: Exon 2 of the gene for neural cell adhesion molecule L1 is alternatively spliced in B cells. Brain Res Mol Brain Res 30: 378-380, 1995.
58. Reid RA and Hemperly JJ: Variants of human L1 cell adhesion molecule arise through alternate splicing of RNA. J Mol Neurosci 3: 127-135, 1992.
59. Hauser S, Bickel L, Weinspach D, Gerg M, Schäfer MK, Pfeifer M, Hazin J, Schelter F, Weidle UH, Ramser J, Volkmann J, Meindl A, Schmitt M, Schrötzlmeier F, Altevogt P and Krüger A: Full-length LlCAM and not its Δ2Δ27 splice variant promotes metastasis through induction of gelatinase expression. PLoS ONE 6, e18989, 2011.
60. Tsukita S, Furuse M and Itoh M: Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol 2: 285-293, 2001. (Pubitemid 33676971)
61. Niimi T, Nagashima K, Ward JM, Minoo P, Zimonjic DB, Popescu NC and Kimura S: Claudin-18, a novel downstream target gene for the T/EBP/NKX2.1 homeodomain transcription factor, encodes lung- and stomach-specific isoforms through alternative splicing. Mol Cell Biol 21: 7380-7390, 2001. (Pubitemid 32958540)
62. Sahin U, Koslowski M, Dhaene K, Usener D, Brandenburg G, Seitz G, Huber C and Türeci O: Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res 14: 7624-3764, 2008.
63. Klamp T, Schumacher J, Huber G, Kühne C, Meissner U, Selmi A, Hiller T, Kreiter S, Markl J, Türeci Ö and Sahin U: Highly specific auto-antibodies against claudin-18 isoform 2 induced by a chimeric HBcAg virus-like particle vaccine kill tumor cells and inhibit the growth of lung metastases. Cancer Res 71: 516-527, 2011.
64. Ponta H and Herrlich P: The CD44 protein family: roles in embryogenesis and tumor progression. Bioscience 3: 650-656, 1998.
65. Herrlich P, Morrison H, Sleeman J, Orian-Rousseau V, König H, Weg-Remers S and Ponta H: CD44 acts both as a growth- and invasiveness-promoting molecule and as a tumor-suppressing cofactor. Ann NY Acad Sci 910: 106-120, 2006
66. Ponta H, Sherman L and Herrlich PA: CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 4: 33-45, 2003. (Pubitemid 36077255)
67. Günthert U, Hofmann M, Rudy W, Reber S, Zöller M, Haussmann I, Matzku S, Wenzel A, Ponta H and Herrlich P: A new variant of glycoprotein CD44 confers metastatic potential on rat carcinoma cells. Cell 65: 13-24, 1991. (Pubitemid 121001209)
68. Rudy W, Hofmann M, Schwartz-Albiez R, Zöller M, Heider KH, Ponta H and Herrlich P: The two major CD44 proteins expressed on a metastatic rat tumor cell line are derived from different splice variants: each one individually suffices to confer metastatic behavior. Cancer Res 53: 1262-1268, 1993. (Pubitemid 23097099)
69. Herrlich P, Zöller M, Pals ST and Ponta H: CD44 splice variants: metastases meet lymphocytes. Immunol Today 14: 395-399, 1993. (Pubitemid 23226226)
70. Wielenga VJ, Heider KH, Offerhaus GJ, Adolf GR, van den Berg FM, Ponta H, Herrlich P and Pals ST: Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res 53: 4754-4756, 1993. (Pubitemid 23326158)
71. Kim H, Yang XL, Rosada C, Hamilton SR and August JT: CD44 expression in colorectal adenomas is an early event occurring prior to K-ras and p53 gene mutation. Arch Biochem Biophys 310: 504-507, 1994. (Pubitemid 24172699)
72. Koopman G, Heider KH, Horst E, Adolf GR, van den Berg F, Ponta H, Herrlich P and Pals ST: Activated human lymphocytes and aggressive non-Hodgkin's lymphomas express a homologue of the rat metastasis-associated variant of CD44. J Exp Med 177: 897-904, 1993. (Pubitemid 23097379)
73. Simon JC, Heider KH, Dietrich A, Wuttig C, Schöpf E, Adolf GR, Ponta H and Herrlich P: Expression of CD44 isoforms in human skin cancer. Eur J Cancer 32A: 1394-1400, 1996. (Pubitemid 26246716)
74. Heider KH, Sproll M, Susani S, Patzelt E, Beaumier P, Ostermann E, Ahorn H and Adolf GR: Characterization of a high-affinity monoclonal antibody specific for CD44v6 as candidate for immunotherapy of squamous cell carcinomas. Cancer Immunol Immunother 43: 245-253, 1996. (Pubitemid 26426258)
75. Börjesson PK, Postema EJ, Roos JC, Colnot DR, Marres HA, van Schie MH, Stehle G, de Bree R, Snow GB, Oyen WJ and van Dongen GA: Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. Clin Cancer Res 9: 3961S-3972S, 2003. (Pubitemid 37169203)
76. Tijink BM, Buter J, de Bree R, Giaccone G, Lang MS, Staab A, Leemans CR and van Dongen GA: A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res 12: 6064-6072, 2006. (Pubitemid 44703770)
77. Naor D, Sionov RV and Ish-Shalom D: CD44: structure, function, and association with the malignant process. Adv Cancer Res 71: 241-319, 1997. (Pubitemid 27197761)
78. Bellahcene A, Castronovo V, Ogbureke KUE, Fisher LW and Fedarko NS: Small integrin-binding ligand N-linked glycoproteins (SIBLINGS): multifunctional proteins in cancer. Nat Rev Cancer 8: 212-226, 2008. (Pubitemid 351301854)
79. Courter D, Cao H, Kwok S, Kong C, Kuo P, Bouley DM, Vice C, Brustugun OT, Denko NC, Kong AC, Giacca A and Le QT: The RGD domain of human osteopontin promotes tumor growth and metastasis through activation of survival pathways. PLoS ONE (oneline), e9633, 2010.
80. Brooks PC, Clark PA and Cheresh DA: Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264: 569-571, 1994.
81. Till TM, Franco VF, Robbs BK, Wanderley JL, da Silva FR, de Mello KD, Viola JP, Weber GF and Gimba ER: Osteopontin-c splicing isoform contributes to ovarian cancer progression. Mol Cancer Res 9: 280-293, 2011.
82. Sullivan J, Blair L, Alnajar A, Aziz T, Ng CY, Chipitsyna G, Gong Q, Witkiewitz A, Weber GF, Denhardt DT, Yeo CJ and Arafat HA: Expression of prometastatic splice variant of osteopontin, OPNC, in human pancreatic ductal adenocarcinoma. Surgery 146: 232-240, 2009.
83. Yan W, Qian CX, Zhao P, Shi L, Qian J, Liu N, Fu Z, Kang C, Pu P and You P: Expression pattern of osteopontin splice variants and its functions om cell apoptosis and invasion of glioma cells. Neuro Oncol 12: 765-775, 2010.
84. He B, Mirza M and Weber GF: An osteopontin splice variant induces anchorage independence in human breast cancer cells. Oncogene 25: 2192-2202, 2008.
85. Chae S, Jun HO, Lee EG, Yeng SJ, Lee DC, Jung JK, Park KC, Yeom YI and Kim KW: Osteopontin splice variants modulate the migratory activity of hepatocellular carcinoma cell lines. Int J Oncol 35: 1409-1416. 2009.
86. Rahmani M, Wong BW, Ang L, Cheung CC, Carthy JM, Walinski H and McManus BM: Versican: signaling to transcriptional control pathways. Can J Physiol Pharmacol 84: 77-92, 2006. (Pubitemid 44011953)
87. Wight TN: Versican: a versatile extracellular matrix proteoglycan in cell biology. Curr Opin Cell Biol 14: 617-623, 2002.
88. Wu YJ, La Pierre DP, Wu J, Yee AJ and Yang BB: The interaction of versican with its binding partners. Cell Res 15: 483-494, 2005. (Pubitemid 41653919)
89. Zimmermann DR and Ruoslahti E: Multiple domains of the large fibroblast proteoglycan, versican. EMBO J 8: 2975-2981, 1989. (Pubitemid 19274999)
90. Kischel P, Waltregny D, Dumont B, Turtoi A, Greffe Y, Kirsch S, De Pauw E and Castronovo V: Versican overexpression in human breast cancer lesions: known and new isoforms for stromal tumor targeting. Int J Cancer 126: 640-650, 2010.
91. Naso MF, Zimmermann DR and Iozzo RV: Characterization of the complete genomic structure of the human versican gene and functional analysis of its promoter. J Biol Chem 269: 32999-33008, 1994.
92. Dours-Zimmermann MT and Zimmermann DR: A novel glycosaminoglycan attachment domain identified in two alternative splice variants of human versican. J Biol Chem 269: 32992-32998, 1994.
93. Cattaruzza S, Schiappacassi M, Ljungberg-Rose A, Spessotto P, Perissinotto D, Mörgelin M, Mucignat MT, Colombatti A and Perris R: Distribution of PG-M/versican variants in human tissues and de novo expression of isoform V3 upon endothelial cell activation, migration, and neoangiogenesis in vitro. J Biol Chem 277: 47626-47635, 2002. (Pubitemid 36159284)
94. Schmalfeldt M, Dours-Zimmermann MT, Winterhalter KH and Zimmermann DR: Versican V2 is a major extracellular matrix component of the mature bovine brain. J Biol Chem 273: 15758-15764, 1998. (Pubitemid 28298196)
95. Kim S, Takahashi H, Lin WW, Descargues P, Grivennikov S, Kim Y, Luo JL and Karin M: Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 457: 102-106, 2009.
96. Pankov R and Yamada KM: Fibronectin at a glance. J Cell Sci 115: 3861-3863, 2002. (Pubitemid 35256486)
97. Singh P, Carraher C and Schwarzbauer JE: Assembly of fibronectin extracellular matrix. Annu Rev Cell Dev Biol 26: 397-419, 2010.
98. Cabodi S, del Pilar Camacho-Leal M, Di Stefano P and Defilippi P: Integrin signalling adaptors: not only figurants in the cancer story. Nat Rev Cancer 10: 858-870, 2010.
99. Ebbinghaus C, Scheuermann J, Neri D and Elia G: Diagnostic and therapeutic applications of recombinant antibodies: targeting the extra-domain B of fibronectin, a marker of tumor angiogenesis. Curr Pharm Des 10: 1537-1549, 2004. (Pubitemid 38559765)
100. Neri D and Bicknell R: Tumour vascular targeting. Nat Rev Cancer 5: 436-446, 2005. (Pubitemid 40791486)
101. Kriegsmann J, Berndt A, Hansen T, Borsi L, Zardi L, Bräuer R, Petrow PK, Otto M, Kirkpatrick CJ, Gay S and Kosmehl H: Expression of fibronectin splice variants and oncofetal glycosylated fibronectin in the synovial membranes of patients with rheumatoid arthritis and osteoarthritis. Rheumatol Int 24: 25-33, 2004. (Pubitemid 38168110)
102. Pini A, Viti F, Santucci A, Carnemolla B, Zardi L, Neri P and Neri D: Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem 273: 21769-21776, 1998. (Pubitemid 28405353)
103. Tarli L, Balza E, Viti F, Borsi L, Castellani P, Berndorff D, Dinkelborg L, Neri D and Zardi L: A high-affinity human antibody that targets tumoral blood vessels. Blood 94: 192-198, 1999. (Pubitemid 29300149)
104. Santimaria M, Moscatelli G, Viale GL, Giovannoni L, Neri G, Viti F, Leprini A, Borsi L, Castellani P, Zardi L, Neri D and Riva P: Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res 9: 571-579, 2003. (Pubitemid 36182586)
105. Tijink BM, Neri D, Leemans CR, Budde M, Dinkelborg LM, Stigter-van Walsum M, Zardi L and van Dongen GAMS: Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature. J Nucl Med 47: 1127-1135, 2006. (Pubitemid 47544908)
106. Carnemolla B, Borsi L, Balza E, Castellani P, Meazza R, Berndt A, Ferrini S, Kosmehl H, Neri D and Zardi L: Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood 99: 1659-1665, 2002. (Pubitemid 34533039)
107. Borsi L, Balza E, Carnemolla B, Sassi F, Castellani P, Berndt A, Kosmehl H, Biro A, Siri A, Orecchia P, Grassi J, Neri D and Zardi L: Selective targeted delivery of TNFalpha to tumor blood vessels. Blood 102: 4384-4392, 2003. (Pubitemid 37494099)
108. Sommavilla R, Pasche N, Trachsel E, Giovannoni L, Roesli C, Villa A, Neri D and Kaspar M: Expression, engineering and characterization of the tumor-targeting heterodimeric immunocytokine F8-IL12. Protein Eng Des Sel 23: 653-661, 2010.
109. Halin C, Rondini S, Nilsson F, Berndt A, Kosmehl H, Zardi L and Neri D: Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat Biotechnol 20: 264-269, 2002. (Pubitemid 34205419)
110. Johannsen M, Spitaleri G, Curigliano G, Roigas J, Weikert S, Kempkensteffen C, Roemer A, Kloeters C, Rogalla P, Pecher G, Miller K, Berndt A, Kosmehl H, Trachsel E, Kaspar M, Lovato V, González-Iglesias R, Giovannoni L, Menssen HD, Neri D and de Braud F: The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. Eur J Cancer 46: 2926-2935, 2010.
111. Chiquet-Ehrismann R: Tenascins. Int J Biochem Cell Biol 36: 986-990, 2004.
112. Brack SS, Silacci M, Birchler M and Neri D: Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res 12: 3200-3208, 2006. (Pubitemid 43837370)
113. Nies DE, Hemesath TJ, Kim JH, Gulcher JR and Stefansson K: The complete cDNA sequence of human hexabrachion (Tenascin). A multidomain protein containing unique epidermal growth factor repeats. J Biol Chem 266: 2818-2823, 1991. (Pubitemid 21909140)
114. Borsi L, Carnemolla B, Nicolò G, Spina B, Tanara G and Zardi L: Expression of different tenascin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int J Cancer 52: 688-692, 1992.
115. Balza E, Siri A, Ponassi M, Caocci F, Linnala A, Virtanen I and Zardi L: Production and characterization of monoclonal antibodies specific for different epitopes of human tenascin. FEBS Lett 332: 39-43, 1993. (Pubitemid 23295894)
116. Berndt A, Anger K, Richter P, Borsi L, Brack S, Silacci M, Franz M, Wunderlich H, Gajda M, Zardi L, Neri D and Kosmehl H: Differential expression of tenascin-C splicing domains in urothelial carcinomas of the urinary bladder. J Cancer Res Clin Oncol 132: 537-546, 2006. (Pubitemid 43938338)
117. Brack SS, Silacci M, Birchler M and Neri D: Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res 12: 3200-3208, 2006. (Pubitemid 43837370)
118. Silacci M, Brack SS, Späth N, Buck A, Hillinger S, Arni S, Weder W, Zardi L and Neri D: Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo. Protein Eng Des Sel 19: 471-478, 2006. (Pubitemid 44408907)
119. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000. (Pubitemid 30046295)
120. Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell 144: 646-674, 2011.
121. Fluge O, Haugen DRF, Akslen LA, Marstad A, Santoro M, Fusco A, Varhaug JE and Lillehaug JR: Expression and alternative splicing of c-ret RNA in papillary thyroid carcinomas. Oncogene 20: 885-892, 2001. (Pubitemid 32198183)
122. Luther T, Kotzsch M, Meye A, Langerholc T, Füssel S, Olbricht N, Albrecht S, Ockert D, Muehlenweg B, Friedrich K, Grosser M, Schmitt M, Baretton G and Magdolen V: Identification of a novel urokinase receptor splice variant and its prognostic relevance in breast cancer. Thromb Haemost 89: 705-717, 2003. (Pubitemid 36456968)
123. Kotzsch M, Sieuwerts AM, Grosser M, Meye A, Fuessel S, Meijer-van Gelder ME, Smid M, Schmitt M, Baretton G. Lumer T, Magdolen V and Foekens JA: Urokinase receptor splice variant uPAR-del4/5-associated gene expression in breast cancer: identification of rab31 as an independent prognostic factor. Breast Cancer Res Treat 111: 229-240, 2007.
124. Sato S, Kopitz C, Grismayer B, Beaufort N, Reuning U, Schmitt M, Luther T, Kotzsch M, Krüger A and Magdolen V: Overexpression of the urokinase receptor mRNA splice variant uPAR-del4/5 affects tumor-associated processes of breast cancer cells in vitro and in vivo. Breast Cancer Res Treat 127: 649-657, 2010.